The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 19, 2017

Filed:

Jul. 19, 2012
Applicants:

Zdravka Medarova, Metheun, MA (US);

Mehmet V. Yigit, Delmar, NY (US);

Anna Moore, Stoneham, MA (US);

Inventors:

Zdravka Medarova, Metheun, MA (US);

Mehmet V. Yigit, Delmar, NY (US);

Anna Moore, Stoneham, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/51 (2006.01); A61K 31/713 (2006.01); A61K 49/18 (2006.01); A61K 9/50 (2006.01); A61K 31/7115 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 9/00 (2006.01); A61K 47/48 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); B82Y 5/00 (2011.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 9/51 (2013.01); A61K 9/0009 (2013.01); A61K 9/5036 (2013.01); A61K 9/5063 (2013.01); A61K 9/5115 (2013.01); A61K 31/713 (2013.01); A61K 31/7115 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/48238 (2013.01); A61K 47/48861 (2013.01); A61K 49/1824 (2013.01); A61N 5/10 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); A61K 2039/505 (2013.01); B82Y 5/00 (2013.01); C12N 2310/11 (2013.01); C12N 2310/113 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/351 (2013.01); C12N 2320/31 (2013.01); C12N 2320/32 (2013.01);
Abstract

Provided herein are therapeutic nanoparticles having a diameter of between 10 nm to 30 nm, and containing a polymer coating, and a nucleic acid containing a sequence complementary to a sequence within a micro-RNA identified as having a role in cancer cell metastasis or anti-apoptotic activity in a cancer cell (e.g., miR-10b) or a sequence within an mRNA encoding a pro-apoptotic protein that is covalently linked to the nanoparticle. Also provided are pharmaceutical compositions containing these therapeutic nanoparticles. Also provided herein are methods of decreasing cancer cell invasion or metastasis in a subject having a cancer and methods of treating a metastatic cancer in a lymph node in a subject that require the administration of these therapeutic nanoparticles to a subject.


Find Patent Forward Citations

Loading…